AI-driven retrosynthesis integrated into Discovery Chemistry

Sai Life Sciences has entered into a collaboration with Chemical.AI, a technology company specialising in computer-aided synthesis design, to integrate an AI-driven retrosynthesis platform into its Discovery Chemistry workflows. The integration enables medicinal chemists to evaluate synthetic routes more rapidly and explore a broader set of feasible pathways during early-stage drug discovery.

Retrosynthesis is a critical and judgment-intensive step in compound design. The platform analyzes reaction precedents, assesses synthetic feasibility, and proposes alternative disconnection strategies within minutes. This provides structured, data-supported route options that chemists can review, refine, and prioritize based on program objectives.

By embedding AI-assisted retrosynthetic analysis directly into project workflows, Sai Life Sciences enables earlier alignment between biological hypotheses and practical synthetic execution. The integration supports more efficient design–make–test cycles, reduces avoidable iteration, and strengthens decision-making across hit-to-lead and lead optimization stages. The collaboration represents a targeted expansion of digital enablement within Discovery Chemistry while maintaining scientist-led route selection and experimental validation.